SGMOQ — Sangamo Therapeutics Share News
0.000.00%
Last trade - 00:00- $18.64m
- -$8.94m
- $39.55m
Brief: Pfizer Announces Positive Topline Results From Phase 3 Study Of Hemophilia A Gene Therapy Candidate
Sangamo Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Sangamo Therapeutics Q1 Operating Income USD -51.526 Million
Sangamo Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview
Sangamo Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview
Brief: Sangamo Therapeutics Entered Into A Securities Purchase Agreement With Institutional Investors
Sangamo Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Blood-brain Barrier Penetration, Brain Transduction in NHPs
Brief: Sangamo Therapeutics Q4 EPS USD -0.34
Sangamo Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Sangamo Therapeutics Announces U.S. FDA Alignment On Abbreviated Pathway To Potential Approval For St-920 In Fabry Disease
Brief: Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data In Fabry Disease
Brief: Sangamo Therapeutics Says It Determined Not To Award Annual Cash Bonus, With Respect To 2023 Co Performance, To Co's Executive Officers, Including CEO, CFO
Sangamo Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Sangamo Therapeutics Q3 EPS USD -0.59
Sangamo Therapeutics Inc expected to post a loss of 32 cents a share - Earnings Preview
Sangamo Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Sangamo Therapeutics Q2 EPS USD -0.66
Sangamo Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview